Is AGLE or EQR a better dividend investment in 2026?

AGLE currently yields 16.65% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: AGLE offers higher current income.

What is the dividend yield difference between AGLE and EQR?

AGLE has a forward dividend yield of 16.65% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 11.92 percentage points.

Home › Compare › AGLE vs EQR

AGLE vs EQR: Dividend Comparison 2026

AGLE yields 16.65% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AGLE wins by $18.9K in total portfolio value

INVESTMENT

TIME HORIZON10 years

AGLE

● Live price

16.65%

Share price

$12.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$59.3K

Annual income

$4,631.17

Full AGLE calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — AGLE vs EQR

📍 AGLE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AGLE	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AGLE + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AGLE pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGLE

Annual income on $10K today (after 15% tax)

$1,415.49/yr

After 10yr DRIP, annual income (after tax)

$3,936.49/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, AGLE beats the other by $689.83/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGLE + EQR for your $10,000?

AGLE: 50%EQR: 50%

100% EQR50/50100% AGLE

Portfolio after 10yr

$49.9K

Annual income

$4,225.39/yr

Blended yield

8.47%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AGLE

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-1.2

Piotroski

3/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGLE buys

EQR buys

No recent congressional trades found for AGLE or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAGLEEQR

Forward yield	16.65% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$59.3K ✓	$40.5K
Annual income after 10y	$4,631.17 ✓	$3,819.61
Total dividends collected	$30.5K ✓	$16.9K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Hold	Hold

Year-by-year: AGLE vs EQR ($10,000, DRIP)

Year	AGLE Portfolio	AGLE Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$12,365	$1,665.28	$11,248	$547.57	+$1.1K → AGLE
2	$15,155	$1,924.45	$12,701	$666.53	+$2.5K → AGLE
3	$18,421	$2,204.37	$14,405	$814.59	+$4.0K → AGLE
4	$22,214	$2,504.02	$16,413	$999.84	+$5.8K → AGLE
5	$26,591	$2,822.14	$18,795	$1,232.92	+$7.8K → AGLE
6	$31,610	$3,157.22	$21,639	$1,527.95	+$10.0K → AGLE
7	$37,330	$3,507.56	$25,057	$1,903.80	+$12.3K → AGLE
8	$43,814	$3,871.31	$29,197	$2,385.87	+$14.6K → AGLE
9	$51,128	$4,246.52	$34,250	$3,008.70	+$16.9K → AGLE
10	$59,338	$4,631.17	$40,467	$3,819.61	+$18.9K → AGLE

AGLE vs EQR: Complete Analysis 2026

AGLE — Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Full AGLE Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this AGLE vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGLE vs SCHD AGLE vs JEPI AGLE vs O AGLE vs KO AGLE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.